Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRISe-5: TAR-200 vs intravesical chemotherapy in high-risk NMIBC after BCG
jRCT2011240009Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing TAR-200 with Mitomycin C or Gemcitabine (2 arms). Primary endpoint: Disease-free Survival (DFS). Started Jun 2024; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemmitomycin cgemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2011240009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240009.